<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137846">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885481</url>
  </required_header>
  <id_info>
    <org_study_id>B-1304-199-001</org_study_id>
    <nct_id>NCT01885481</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone in Patients With Spinal Pain: a Prospective, Randomized, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Particle steroid drug such as triamcinolone has been used widely for epidural steroid
      injection (ESI) treatment in Korea. However, Korea FDA recently prohibit ESI using
      triamcinolone, following the regulation of US FDA. Therefore, dexamethasone and
      betamethasone become only candidate drugs for ESI in Korea and the investigators are curious
      about the effectiveness and safety of both drugs due to limitation of information about
      comparison of two drugs in previous literature. So, this study aims to compare the
      effectiveness and safety of both drugs and our hypothesis is that there is no difference of
      the effectiveness between dexamethasone and betamethasone at 2 weeks after ESI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>rate of patients with pain improvement</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>rate of patients with significant pain improvement at 2 week time point after epidural steroid injection, with the patients' subjective satisfaction scale of &quot;much improved&quot; or &quot;no pain&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence of adverse event during 12 weeks after epidural steroid injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain decrease</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>decrease of NRS (numeric rating scale) for pain at 2 week time point after epidural steroid injection, compared to baseline NRS at 0 week</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Spinal Pain</condition>
  <arm_group>
    <arm_group_label>dexa-ESI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epidural steroid injection using dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>beta-ESI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epidural steroid injection using betamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>epidural steroid injection using dexamethasone</description>
    <arm_group_label>dexa-ESI</arm_group_label>
    <other_name>dexamethasone-ESI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>epidural steroid injection using betamethasone</description>
    <arm_group_label>beta-ESI</arm_group_label>
    <other_name>betamethasone-ESI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients with spinal pain (i.e.neck pain, back pain, or radiculopathy..)

          2. patients with informed consent

          3. VAS (visual analog scale) is five or more in 10-point scale at screening

          4. sustained spinal pain, regardless of sufficient conservative treatment (i.e. oral
             medicine, physical therapy..)

        Exclusion Criteria:

          1. age of patient less than 19 years

          2. relative contraindication of epidural steroid injection, as follows:

               -  pregnant or breast-feeding state

               -  uncontrolled coagulopathy

               -  suspected of active infection state

               -  uncontrolled diabetes mellitus

               -  previous history of adverse event related to epidural steroid injection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joon Woo Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joon Woo Lee, MD</last_name>
    <phone>82-31-787-7616</phone>
    <email>joonwoo2@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guen Young Lee, MD</last_name>
    <phone>82-31-787-7630</phone>
    <email>netty0523@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>763-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Woo Lee, MD</last_name>
      <phone>82-31-787-7616</phone>
      <email>joonwoo2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joon Woo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Joon Woo Lee</investigator_full_name>
    <investigator_title>Associate professor, Department of Radiology</investigator_title>
  </responsible_party>
  <keyword>dexamethasone</keyword>
  <keyword>betamethasone</keyword>
  <keyword>epidural steroid injection</keyword>
  <keyword>comparative effectiveness research</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
